Scarica l'app Stockscreener
0.7216
0.22%
0.0016
Dopo l'orario di chiusura:
.72
-0.0016
-0.22%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Vistagen Therapeutics Inc Borsa (VTGN) Ultime notizie
Lost Money on Vistagen Therapeutics, Inc.(VTGN)? You May Have Been Affected by FraudContact Levi & Korsinsky - ACCESS Newswire
VistaGen’s PALISADE-3 trial fails primary endpoint in SAD - MSN
Aug Volume: Should I hold or sell Vistagen Therapeutics Inc stock in 2025July 2025 Intraday Action & Stepwise Trade Execution Plans - moha.gov.vn
VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q3 2025 Earnings Call Transcript - MSN
VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Sees Large Increase in Short Interest - Defense World
Vistagen Therapeutics Inc (VTGN) deserves deeper analysis - uspostnews.com
ATTENTION VTGN SHAREHOLDERS: Investors who Lost Money on Vistagen Therapeutics, Inc. are Urged to Contact Levi & Korsinsky about an Ongoing Investigation - ACCESS Newswire
Lost Money on Vistagen Therapeutics, Inc.(VTGN)? Contact Levi & Korsinsky Regarding an Ongoing Investigation - ACCESS Newswire
Vistagen Therapeutics (VTGN) price target decreased by 50.00% to 7.40 - MSN
VTGN STOCK ALERT: Levi & Korsinsky Notifies Vistagen Therapeutics, Inc. Investors of an Ongoing Investigation - ACCESS Newswire
William Blair downgrades Vistagen Therapeutics (VTGN) - MSN
Finance Watch: Vistagen To Cut Costs After Phase III Trial Failure - Citeline News & Insights
Levi & Korsinsky Announces an Investigation on Behalf of Vistagen Therapeutics, Inc. (VTGN) Shareholders Who May Have Been Affected by Fraud - ACCESS Newswire
Vistagen Therapeutics reports Phase 3 trial for fasedienol did not meet endpoint - Investing.com Australia
Vistagen Therapeutics reports Phase 3 trial for fasedienol did not meet endpoint By Investing.com - Investing.com South Africa
VistaGen’s PALISADE-3 Trial Fails Primary Endpoint in SAD - TipRanks
Vistagen Therapeutics Reports Phase 3 Study Results - TradingView — Track All Markets
Vistagen Therapeutics, Inc. (VTGN) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights - ACCESS Newswire
How Vistagen Therapeutics Inc. stock reacts to bond yieldsWeekly Trade Analysis & Daily Growth Stock Investment Tips - Улправда
Can Vistagen Therapeutics Inc. stock sustain institutional interestJuly 2025 Selloffs & Reliable Momentum Entry Alerts - Улправда
Update Recap: Why retail investors pile into Vistagen Therapeutics Inc. stockPortfolio Performance Report & Accurate Entry and Exit Point Alerts - Улправда
Can Vistagen Therapeutics Inc. stock deliver consistent earnings growth2025 Sector Review & Momentum Based Trading Signals - Улправда
Can Vistagen Therapeutics Inc. stock beat analyst upgrades2025 Price Momentum & Precise Entry and Exit Recommendations - DonanımHaber
Why retail investors pile into Vistagen Therapeutics Inc. stockJuly 2025 Spike Watch & Verified Swing Trading Watchlists - Улправда
Aug Selloffs: What Wall Street predicts for Vistagen Therapeutics Inc. stock priceQuarterly Portfolio Review & Daily Growth Stock Tips - Улправда
VTGN ACTIVE INVESTIGATION: Lost Money on Vistagen Therapeutics, Inc.? Contact Levi & Korsinsky Now - ACCESS Newswire
Shareholders Alert: Investigation Into Vistagen Therapeutics, Inc. (VTGN)Contact Levi & Korsinsky to Protect Your Rights - ACCESS Newswire
Vistagen tanks after fasedienol Phase III miss - The Pharma Letter
Jefferies Downgrades Vistagen Therapeutics to Hold From Buy, Adjusts Price Target to $0.90 From $15 - marketscreener.com
Vistagen appoints Nick Tressler as CFO - MSN
Vistagen Therapeutics (VTGN) Receives Downgrade from William Bla - GuruFocus
Vistagen downgraded to market perform from outperform at William Blair - MSN
VistaGen Therapeutics trading resumes - MSN
Downgrade Alert: Vistagen Therapeutics (VTGN) Target Price Slashed | VTGN Stock News - GuruFocus
Vistagen stock craters after social anxiety study comes up empty - FirstWord Pharma
Vistagen Therapeutics (VTGN) Downgraded by Maxim Group | VTGN St - GuruFocus
Vistagen (VTGN) Stock: Plunges 79% After Disappointing Phase 3 Trial Results - parameter.io
Jefferies downgrades VistaGen stock rating to Hold on failed Phase III trial - Investing.com
VistaGen stock rating downgraded by William Blair after trial miss - Investing.com Canada
Vistagen phase 3 study sees placebo surprise, putting future of social anxiety asset into question: analyst - Fierce Biotech
Vistagen’s anxiety treatment fails to meet primary endpoint in trial By Investing.com - Investing.com Nigeria
Fasedienol for Social Anxiety Disorder Does Not Demonstrate Significant Improvement in Phase 3 Study - Psychiatric Times
Maxim Downgrades Vistagen Therapeutics to Hold From Buy - marketscreener.com
William Blair Downgrades VistaGen Therapeutics(VTGN.US) to Hold Rating - 富途牛牛
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Stifel downgrades VistaGen stock to Hold as anxiety drug fails in trial - Investing.com Canada
Vistagen downgraded to Hold at Stifel after PALISADE-3 study disappoints - TipRanks
Why Did Vistagen Stock Tank 82% Today? - Stocktwits
Vistagen (VTGN) Faces Setback as Phase 3 Trial Misses Primary En - GuruFocus
Vistagen downgraded to Neutral from Buy at Lucid Capital - TipRanks
Vistagen (VTGN) Phase 3 Study Results for Social Anxiety Treatme - GuruFocus
Vistagen SAD study did not achieve primary endpoint - TipRanks
Vistagen’s anxiety treatment fails to meet primary endpoint in trial - Investing.com
Vistagen Therapeutics Earnings Notes - Trefis
Vistagen announces topline results from Palisade-3 Phase 3 study - marketscreener.com
2.52%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):